Absorption: After oral administration, Alprazolam is readily absorbed.

This invention concerns a new formulation for racecadotril in the form of tablets, including the preparation process and their use for treating diarrhea.

· Loperamide should not be used in cases of diarrhea occurring during broad-spectrum antibiotic therapy.

The bioavailability of Racecadotril is not modified by food, but the peak of activity is delayed for 1.5 hours approximately.

The bioavailability of Racecadotril is not modified by food, but the peak of activity is delayed for 1.5 hours approximately.

Concomitant use of other NEP inhibitors (e.g. racecadotril) and ACE inhibitors may also increase the risk of angioedema (see section 4.5).

Concomitant use of other NEP inhibitors (e.g. racecadotril) and ACE inhibitors may also increase the risk of angioedema (see section 4.5).

Concomitant use of other NEP inhibitors (e.g. racecadotril) and ACE inhibitors may also increase the risk of angioedema (see section 4.5).

The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea.

Racecadotril protects enkephalins from enzymatic degradation thereby prolonging their action at enkephalinergic synapses in the small intestine and reducing hypersecretion.

Racecadotril has not been tested in antibiotic-associated diarrhea and should therefore not be administered under these conditions.

Racecadotril protects enkephalins from enzymatic degradation thereby prolonging their action at enkephalinergic synapses in the small intestine and reducing hypersecretion.

Hence, a careful benefit-risk assessment is needed before initiating treatment with NEP inhibitors (e.g. racecadotril) in patients on quinapril.

The aim of this Cochrane Review was to find out whether racecadotril works for children under five years of age with diarrhoea.

Hence, a careful benefit-risk assessment is needed before initiating treatment with NEP inhibitors (e.g. racecadotril) in patients on quinapril.